Results 11 to 20 of about 159,317 (346)

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Cholangiocarcinoma (CCA) is the second most common primary liver cancer and associated with a dismal prognosis due to the lack of an efficient systemic therapy. In contrast to other cancers, new immunotherapies have demonstrated unsatisfactory results in
Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch   +8 more
doaj   +5 more sources

Tumor-infiltrating lymphocytes for melanoma immunotherapy

OncoImmunology, 2023
Oliver Kepp, Peng Liu, Laurence Zitvogel, Guido Kroemer   +3 more
doaj   +4 more sources

Role of tumor-infiltrating lymphocytes in melanoma

Turkish Journal of Plastic Surgery, 2019
Yasemin Benderli Cihan
doaj   +2 more sources

Tumor Infiltrating Lymphocytes in Ovarian Cancer [PDF]

Asian Pacific Journal of Cancer Prevention, 2015
Several improvements in ovarian cancer treatment have been achieved in recent years, both in surgery and in combination chemotherapy with targeting. However, ovarian tumors remain the women's cancers with highest mortality rates. In this scenario, a pivotal role has been endorsed to the immunological environment and to the immunological mechanisms ...
GASPARRI, MARIALUISA, Attar, R, PALAIA, INNOCENZA, PERNIOLA, GIORGIA, Marchetti, C, DI DONATO, VIOLANTE, Farooqi, Aa, Papadia, A, BENEDETTI PANICI, PIERLUIGI   +8 more
openaire   +8 more sources

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma [PDF]

New England Journal of Medicine, 2022
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking ...
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen   +56 more
openaire   +10 more sources

Tumor-Infiltrating Lymphocytes in Melanoma [PDF]

Current Oncology Reports, 2012
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective treatment for patients with metastatic melanoma. With higher response rates than ipilimumab or IL-2, and longer durations of response than vemurafenib, TIL therapy carries the potential to transform current outcomes in melanoma, while also defining the way ...
Sylvia Lee, Sylvia Lee, Kim Margolin, Kim Margolin   +3 more
openaire   +3 more sources

Tumor-infiltrating lymphocytes in the immunotherapy era [PDF]

Cellular & Molecular Immunology, 2020
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune checkpoint inhibitor therapy in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and more recently, B cell responses within the tumor microenvironment.
S. T. Paijens, Annege Vledder, Hans W. Nijman, Marco de Bruyn   +3 more
openaire   +3 more sources

The biologic importance of tumor‐infiltrating lymphocytes [PDF]

Journal of Cutaneous Pathology, 2010
Detailed pathologic analysis has delineated a close association between intratumoral CD 8+ cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the presence at tumor sites of negative immune regulatory elements, such as FoxP 3+ T cells (Tregs) and PD‐1/PD‐L1 co‐stimulatory molecules, is closely associated with inferior ...
F. Stephen Hodi, Glenn Dranoff
openaire   +2 more sources

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +6 more sources

Epigenetic quantification of tumor-infiltrating T-lymphocytes [PDF]

Epigenetics, 2011
The immune system plays a pivotal role in tumor establishment. However, the role of T-lymphocytes within the tumor microenvironment as major cellular component of the adaptive effector immune response and their counterpart, regulatory T-cells (Treg), responsible for suppressive immune modulation, is not completely understood.
Alexander Mustea, Thorsten Dickhaus, Jörn Gröne, Tatjana I. Cornu, Udo Baron, Martin Kruschewski, Sven Olek, Ivana Türbachova, Christoph Loddenkemper, Jalid Sehouli, Andreas Grützkau, Tim Schwachula, Philipp Lohneis, Ulrich Hoffmüller   +13 more
openaire   +3 more sources